CEL SCI Financials
CVM Stock | USD 0.69 0.05 6.76% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 1.35 | 1.42 |
|
|
Investors should never underestimate CEL SCI's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor CEL SCI's cash flow, debt, and profitability to make informed and accurate decisions about investing in CEL SCI Corp.
Cash And Equivalents |
|
CEL | Select Account or Indicator |
Understanding current and past CEL SCI Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of CEL SCI's financial statements are interrelated, with each one affecting the others. For example, an increase in CEL SCI's assets may result in an increase in income on the income statement.
CEL SCI Stock Summary
CEL SCI competes with Agenus, Cyclacel Pharmaceuticals, and BioCryst Pharmaceuticals. CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company was incorporated in 1983 and is headquartered in Vienna, Virginia. Cel-Sci Corp operates under Biotechnology classification in the United States and is traded on AMEX Exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NYSE MKT Exchange |
ISIN | US1508376076 |
CUSIP | 150837607 150837508 150837409 |
Location | Virginia; U.S.A |
Business Address | 8229 Boone Boulevard, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | cel-sci.com |
Phone | 703 506 9460 |
Currency | USD - US Dollar |
CEL SCI Key Financial Ratios
Return On Equity | -2.5 | ||||
Price To Sales | 11,797 X | ||||
Gross Profit | (25.36 M) | ||||
EBITDA | (27.56 M) | ||||
Net Income | (32.19 M) |
CEL SCI Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 40.5M | 75.9M | 50.5M | 30.5M | 35.1M | 36.9M | |
Other Current Liab | 102.2K | 863.9K | (417.5K) | 1.6M | 1.8M | 1.8M | |
Net Debt | (1.6M) | (20.1M) | (7.4M) | 9.4M | 8.5M | 8.9M | |
Retained Earnings | (381.8M) | (418.2M) | (454.9M) | (487.1M) | (438.4M) | (416.5M) | |
Cash | 15.5M | 36.1M | 22.7M | 4.1M | 4.8M | 7.7M | |
Other Current Assets | 1.3M | 998.5K | 762.1K | 524.6K | 472.2K | 448.5K | |
Total Liab | 20.8M | 19.3M | 18.4M | 17.3M | 19.9M | 20.9M | |
Total Current Assets | 17.7M | 45.3M | 25.4M | 6.9M | 8.0M | 9.9M | |
Short Term Debt | 2.1M | 1.4M | 3.5M | 2.0M | 2.3M | 1.2M | |
Intangible Assets | 313.4K | 275.9K | 212.2K | 197.7K | 177.9K | 284.1K | |
Accounts Payable | 2.0M | 1.7M | 1.6M | 2.0M | 2.3M | 1.4M | |
Net Receivables | 118.7K | 62.8K | 54.9K | (2.0M) | (1.8M) | (1.7M) | |
Common Stock | 387.3K | 432.1K | 434.5K | 474.2K | 426.8K | 682.4K | |
Other Liab | 7.0M | 6.0M | 3.7M | 125K | 143.8K | 136.6K | |
Inventory | 820.1K | 2.0M | 2.0M | 2.2M | 2.6M | 2.7M | |
Net Tangible Assets | 5.1M | 19.4M | 56.3M | 32.0M | 36.7M | 38.6M | |
Capital Surpluse | 358.5M | 401.2M | 474.3M | 486.6M | 559.6M | 351.9M | |
Long Term Debt Total | 13.5M | 11.8M | 13.3M | 11.7M | 13.5M | 12.5M |
CEL SCI Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 1.0M | 1.1M | 1.1M | 675.4K | 776.7K | 815.6K | |
Gross Profit | 540.8K | (499K) | (3.9M) | (4.0M) | (3.6M) | (3.4M) | |
Operating Income | (29.0M) | (36.2M) | (36.1M) | (31.5M) | (28.3M) | (26.9M) | |
Ebit | (29.0M) | (34.5M) | (35.6M) | (31.5M) | (28.4M) | (26.9M) | |
Ebitda | (26.8M) | (34.0M) | (31.7M) | (27.6M) | (24.8M) | (23.6M) | |
Cost Of Revenue | 17.8K | 499K | 3.9M | 4.0M | 3.6M | 3.1M | |
Net Income | (32.2M) | (39.2M) | (38.3M) | (32.4M) | (29.1M) | (27.7M) | |
Income Tax Expense | 2.0M | 2.8M | 1.6M | 632.6K | 569.3K | 597.8K | |
Income Before Tax | (30.3M) | (36.4M) | (36.7M) | (32.2M) | (29.0M) | (27.5M) | |
Research Development | 17.8M | 23.1M | 25.4M | 22.5M | 25.8M | 27.1M | |
Interest Income | 2.6M | 1.4M | 1.8M | 714.2K | 642.8K | 610.7K | |
Net Interest Income | (1.0M) | (1.1M) | (1.1M) | (675.4K) | (776.7K) | (815.6K) |
CEL SCI Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 7.1M | 20.6M | (13.4M) | (18.5M) | (16.7M) | (15.8M) | |
Free Cash Flow | (18.0M) | (27.8M) | (18.9M) | (23.2M) | (20.9M) | (19.9M) | |
Depreciation | 2.2M | 2.2M | 3.8M | 4.0M | 4.6M | 4.8M | |
Other Non Cash Items | 2.6M | 1.2M | 480.1K | 15.3K | 17.6K | 16.7K | |
Capital Expenditures | 2.7M | 9.0M | 660.6K | 372.3K | 428.1K | 689.7K | |
Net Income | (30.3M) | (36.4M) | (36.7M) | (32.2M) | (29.0M) | (27.5M) | |
End Period Cash Flow | 15.5M | 36.1M | 22.7M | 4.1M | 4.8M | 7.9M | |
Change To Inventory | (37.7K) | (1.2M) | (159.4K) | (156.7K) | (141.1K) | (148.1K) | |
Change Receivables | 99.8K | 55.9K | 7.8K | 54.9K | 63.2K | 66.3K | |
Change To Netincome | 9.6M | 11.0M | 14.9M | 11.8M | 13.6M | 14.3M | |
Net Borrowings | 158.2K | (800.2K) | (1.1M) | (1.4M) | (1.6M) | (1.5M) | |
Investments | (2.7M) | (6.1M) | 6.2M | (372.3K) | (428.1K) | (449.5K) |
CEL Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CEL SCI's current stock value. Our valuation model uses many indicators to compare CEL SCI value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CEL SCI competition to find correlations between indicators driving CEL SCI's intrinsic value. More Info.CEL SCI Corp is rated second in return on equity category among its peers. It is rated fifth in return on asset category among its peers . At this time, CEL SCI's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value CEL SCI by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.CEL SCI Corp Systematic Risk
CEL SCI's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. CEL SCI volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on CEL SCI Corp correlated with the market. If Beta is less than 0 CEL SCI generally moves in the opposite direction as compared to the market. If CEL SCI Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one CEL SCI Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of CEL SCI is generally in the same direction as the market. If Beta > 1 CEL SCI moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in CEL SCI Stock are looking for potential investment opportunities by analyzing not only static indicators but also various CEL SCI's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of CEL SCI growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
CEL SCI December 16, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of CEL SCI help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of CEL SCI Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of CEL SCI Corp based on widely used predictive technical indicators. In general, we focus on analyzing CEL Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build CEL SCI's daily price indicators and compare them against related drivers.
Information Ratio | (0.13) | |||
Maximum Drawdown | 28.0 | |||
Value At Risk | (10.00) | |||
Potential Upside | 8.2 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CEL SCI Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CEL SCI. If investors know CEL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CEL SCI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.63) | Return On Assets (0.61) | Return On Equity (2.50) |
The market value of CEL SCI Corp is measured differently than its book value, which is the value of CEL that is recorded on the company's balance sheet. Investors also form their own opinion of CEL SCI's value that differs from its market value or its book value, called intrinsic value, which is CEL SCI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CEL SCI's market value can be influenced by many factors that don't directly affect CEL SCI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CEL SCI's value and its price as these two are different measures arrived at by different means. Investors typically determine if CEL SCI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CEL SCI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.